Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 113

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 113
---
 | ​    
 2023 
 ​    |       |
|:---------------------------------------|:--|:-----------------------------------------|-----:|:--|:-----|------:|
| MB-102                                 | ​ | $                                        |    — | ​ | $    |   394 |
| MB-106 (2)                             | ​ | ​                                        | -468 | ​ | ​    |    92 |
| MB-107/207 (3)                         | ​ | ​                                        |    — | ​ | ​    |  -389 |
| MB-109                                 | ​ | ​                                        |   72 | ​ | ​    |   356 |
| MB-110                                 | ​ | ​                                        |    — | ​ | ​    |   125 |
| Mayo in situ CAR T                     | ​ | ​                                        |    — | ​ | ​    |     6 |
| All others (4)                         | ​ | ​                                        |   14 | ​ | ​    |    30 |
| Total R&D development expense          | ​ | ​                                        | -382 | ​ | ​    |   614 |
| R&D personnel related expenses         | ​ | ​                                        |  191 | ​ | ​    | 1,826 |
| R&D facility and depreciation expense  | ​ | ​                                        |  260 | ​ | ​    |   398 |
| R&D consulting expenses                | ​ | ​                                        |  -88 | ​ | ​    |   819 |
| R&D lab supplies                       | ​ | ​                                        |   -8 | ​ | ​    | 2,520 |
| R&D other expense (5)                  | ​ | ​                                        |   84 | ​ | ​    | 3,350 |
| Total research and development expense | ​ | $                                        |   57 | ​ | $    | 9,527 |

| (1) | Includes sponsored research, license and clinical trial related costs. |

| (2) | Credit for the three months ended September 30, 2024, primarily reflects the savings on the settlement of payables owed to clinical sites. |

| (3) | Credit for the three months ended September 30, 2023, reflects the refunds and credit memos received upon the termination services for the MB-107/207 program. |

| (4) | Includes costs for long-term follow-up and programs that were terminated. |

| (5)